Cellvizio by Mauna Kea Technologies

Cellvizio by Mauna Kea Technologies Cellvizio is the real-time in vivo cellular imaging platform that revolutionizes the way physicians

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative change in medicine.

This systematic review concludes that nCLE demonstrates strong diagnostic performance in characterising pancreatic cysti...
03/17/2026

This systematic review concludes that nCLE demonstrates strong diagnostic performance in characterising pancreatic cystic lesions, with pooled sensitivity reaching 0.89 (fixed effects) and 0.88 (random effects), specificity ranging between 82–100%.

The authors state that nCLE “improves diagnostic confidence, reduces indeterminate results, and has the potential to positively influence the economy and clinical management.” Meta-analysis confirms high overall accuracy but underscores the need for larger, multicentre validation studies.

Full publication: https://hubs.la/Q046rrvX0

We announce a major milestone for : the CLIMB study has been selected for the prestigious American Society for Gastroin...
03/12/2026

We announce a major milestone for : the CLIMB study has been selected for the prestigious American Society for Gastrointestinal Endoscopy - ASGE Presidential Plenary Session at Digestive Disease Week® (DDW®) 2026!

This multicenter study, led by Dr. Som Krishna, involving over 500 patients across 14 U.S. sites validates the superior diagnostic accuracy of nCLE for pancreatic cystic lesions (PCLs). This recognition underscores Cellvizio’s clinical significance and its role in defining the future of PCL management.

Read the full PR: https://hubs.la/Q046wGfV0

CLIMB study session preview and Dr. Krishna's DDW itinerary: https://hubs.la/Q046wDgM0

This case demonstrates a single session integration of EUS-nCLE for real-time diagnosis and EUS-RFA for immediate therap...
03/10/2026

This case demonstrates a single session integration of EUS-nCLE for real-time diagnosis and EUS-RFA for immediate therapy in a high-risk patient with a branch duct IPMN.

Using nCLE, clinicians identified “flat epithelium and monolayered nuclei” consistent with low-grade dysplasia, achieving approximately 97 percent diagnostic accuracy, and transitioned directly to radiofrequency ablation during the same procedure.
Post ablation imaging showed a 91.6 percent reduction in cyst volume, and next generation sequencing demonstrated resolution of preexisting mutations, confirming a molecular response.

Read more: https://hubs.la/Q0464JrJ0

This study in Surgical Endoscopy via Springer Nature, reveals how probe-based confocal laser endomicroscopy (pCLE) is tr...
03/04/2026

This study in Surgical Endoscopy via Springer Nature, reveals how probe-based confocal laser endomicroscopy (pCLE) is transforming gastrointestinal care at the cellular level. In one key finding, pCLE-guided high-definition endoscopy achieved nearly 2x higher sensitivity for detecting neoplasia in Barrett's esophagus compared to standard protocols.

Explore the expanding role of pCLE ( ) in diagnostics: https://hubs.la/Q045mBP-0

This , we’re spotlighting a shift from "wait-and-see" to "see-and-treat." Why is this more important than ever? This st...
02/26/2026

This , we’re spotlighting a shift from "wait-and-see" to "see-and-treat."

Why is this more important than ever? This study in Gastroenterology highlights the staggering burden of GI diseases, which now cost the U.S. health system over $111 billion annually. With 23.5 million endoscopies performed each year, using advanced tools like to provide faster answers and better outcomes is critical to reducing this burden and saving lives.

Read the study here: https://hubs.la/Q043VxHK0

The data is clear and the results are worth the investment. A recent review in BMJ Open Gastroenterology confirms that E...
02/24/2026

The data is clear and the results are worth the investment. A recent review in BMJ Open Gastroenterology confirms that EUS-nCLE boasts >90% accuracy for pancreatic cystic lesions by providing real-time, microscopic clarity that can prevent unnecessary, high-risk surgeries.

Read in full here: https://hubs.la/Q044r76b0

02/23/2026

We announce a major milestone in our international expansion: Mauna Kea Technologies has officially obtained regulatory clearances for in Switzerland and the United Kingdom.

These approvals open doors to two of Europe’s most strategic markets for interventional gastroenterology. This momentum reinforces our commitment to bringing Cellvizio and to clinicians and patients worldwide. We are entering 2026 with determination!

Read the full PR: https://hubs.la/Q044fX2M0

We had a fantastic Discovery Day at Clinique Paris Bercy! Physicians joined Dr. Maryan Cavicchi to observe live CellTo...
02/18/2026

We had a fantastic Discovery Day at Clinique Paris Bercy! Physicians joined Dr. Maryan Cavicchi to observe live CellTolerance powered by cases on patients with real-time results confirming which patients had and which didn't.

02/10/2026

We are proud to announce that Cellvizio® and its associated probes have officially received CE Mark certification under the European Medical Device Regulation (MDR). Mauna Kea Technologies is the only endomicroscopy company to obtain this certification under the new European regulation.

This major regulatory milestone reinforces our commitment to the highest standards of safety and clinical performance, ensuring continued access to our Cellvizio platform across Europe.

Read the full press release here: https://hubs.la/Q042xVrw0

According to the World Health Organization (WHO), “between 30% and 50% of cancer deaths could be prevented by modifying ...
02/10/2026

According to the World Health Organization (WHO), “between 30% and 50% of cancer deaths could be prevented by modifying or avoiding key risk factors.” Addressing risk factors through early detection is core to our mission at Mauna Kea Technologies, where we strive to transform patient management and care.

Learn more: https://hubs.la/Q041khMY0

02/04/2026

Today we announce key organizational changes to accelerate our international growth. Building on strong 2025 momentum, we've appointed Benoit Chardon as Fractional Chief Commercial Officer to lead the global scale-up of outside the United States.

Following CellTolerance's €1 million sales milestone in 2025, we're entering a focused expansion phase across Europe, the Middle East, and Australia. Simultaneously, we're advancing our pancreatic cyst characterization franchise, leveraging the recent European Society of Gastrointestinal Endoscopy (ESGE) technical guidelines inclusion and strong clinical momentum.

Read the full PR: https://hubs.la/Q041Tsmt0

On World Cancer Day, we join the global effort to raise awareness and unite against cancer; the number one leading cause...
02/04/2026

On World Cancer Day, we join the global effort to raise awareness and unite against cancer; the number one leading cause of death. At Mauna Kea Technologies, we are committed to transforming the way cancer is diagnosed and managed. Learn how can make early cancer detection a reality to improve patient outcomes and long-term prognosis.

To learn more, visit: https://hubs.la/Q041mw6C0

Address

24 Denby Road, Suite 140
Boston, MA
02134

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Cellvizio by Mauna Kea Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.